18.05.2022 14:45:00

Neogen® Launches Enhanced Quantitative Peanut ELISA Assay

New assay provides enhanced detection of high-priority peanut allergen in a wide variety of matrices

LANSING, Mich., May 18, 2022 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that the company has released an enhanced version of the Veratox® for Peanut allergen test, which optimizes sensitivity and flexibility across sample types while maintaining the rapid time-to-result and simple testing procedure standards set by the Veratox product line.

Neogen's new Veratox VIP (Veratox Improvement Platform) for Peanut assay is able to rapidly quantify low levels of peanut protein residues in food products, ingredients, and clean-in-place rinses.

"As the demand for plant-based foods continues to increase, we have seen peanut proteins being processed in more new and creative ways than ever before. However, peanut remains one of the highest-priority allergens in the food industry," said John Adent, Neogen's President and CEO. "It was very important that we offer a solution that gives producers confidence as they navigate this changing landscape. The new Veratox VIP for Peanut assay is very sensitive and able to detect low levels of peanut protein while remaining fast and easy to use."

This innovative quantitative test utilizes the pairing of a unique antibody combination and a modified extraction process to robustly detect levels of peanut protein down to 0.25 ppm. This product has been validated in a wide variety of product types, including both minimally and further-processed products. This flexibility makes the assay appropriate across different food manufacturing and laboratory environments.

About Neogen
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "everyday, protect the people and animals we care about." The company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.

CONTACT: Max Wolf, Product Manager, 800-234-5333, mwolf@neogen.com

Cision View original content:https://www.prnewswire.com/news-releases/neogen-launches-enhanced-quantitative-peanut-elisa-assay-301550076.html

SOURCE NEOGEN Corporation

Analysen zu Neogen Corp.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Neogen Corp. 11,50 0,00% Neogen Corp.